Rocky Mountain Chocolate Factory fails Nasdaq independence rule after director resignation; cure period set

Rocky Mountain Chocolate Factory, Inc.

Received Nasdaq deficiency letter on Nov 14, 2024 for non-compliance with independent director and audit committee requirements under Rule 5605.
Cure period ends earlier of 2025 annual meeting (expected Aug 2025) or Nov 6, 2025.
Stock remains listed on Nasdaq Global Market under RMCF with no immediate delisting effect.
Company intends to appoint an additional independent director to the Board and Audit Committee within the cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.